Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

NCT01931670 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01931670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01931670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
September 9, 2013
Completion date
December 19, 2016
Enrollment
815 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis